A Spark Therapeutics employee in the company's manufacturing facility.

Odylia co-founder Mass Eye performs first post-approval injection of Luxturna®

Massachusetts Eye and Ear says it has performed the first post-approval injection of the Luxturna®, which treats a form of blindness caused by RPE65 deficiency, otherwise known as RP20. The hospital announced on Tuesday that Jason Comander, the associate director of its inherited retinal disorders service, had performed the procedure on a 13-year-old boy

Read Article